Re-Vana Therapeutics is an ocular drug delivery company developing innovative sustained-release technologies to reduce the burden of frequent intravitreal injections and improve outcomes in sight-threatening diseases. Its proprietary photo-crosslinked, biodegradable systems enable 6+ months of controlled drug release across biologics, peptides, and small and large molecules. Founded in 2016 as a spin-out from Queen’s University Belfast, Re-Vana is headquartered in Belfast, Northern Ireland.